1. Home
  2. Stocks
  3. Marksans Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Marksans Pharma Share Price

    Mid Cap
    ₹296.39
    + 2.68 (0.91%)
    18 September, 2024 02:38 BSE: 524404 NSE: MARKSANS ISIN: INE750C01026

    Start SIP in Marksans Pharma

    Start SIP

    Marksans Pharma Performance

    Day Range

    • Low 285
    • High 298
    ₹ 296

    52 Week Range

    • Low 97
    • High 298
    ₹ 296
    • Open Price294
    • Previous Close294
    • Volume3531794

    Marksans Pharma Chart

    • Over 1 Month + 41.81%
    • Over 3 Month + 84.29%
    • Over 6 Month + 103.56%
    • Over 1 Year + 187.62%

    Marksans Pharma Key Statistics

    P/E Ratio 40.2
    PEG Ratio 1.9
    Market Cap Cr
    Price to Book Ratio 6.4
    EPS 3
    Dividend 0.2
    Relative Strength Index 79.72
    Money Flow Index 87.29
    MACD Signal 17.2
    Average True Range 12.56

    Marksans Pharma Investment Rating

    • Master Rating:

    • Marksans Pharma has an operating revenue of Rs. 2,267.99 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 35% and 69% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 91 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Marksans Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 255225241205182153
    Operating Expenses Qtr Cr 213191199167155130
    Operating Profit Qtr Cr 413442372723
    Depreciation Qtr Cr 778854
    Interest Qtr Cr 000001
    Tax Qtr Cr 105913105
    Net Profit Qtr Cr 323325314418
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 915716
    Operating Expenses Annual Cr 713563
    Operating Profit Annual in Cr 14092
    Depreciation Cr 2917
    Interest Annual Cr 14
    Tax Annual Cr 3829
    Net Profit Annual Cr 134103
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 3452
    Cash from Investing Activity Annual Cr -114-195
    Cash from Financing Annual Activity Cr -26210
    Net Cash Flow Annual Cr -10667
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,2231,111
    Fixed Assets Annual Cr 272148
    Total Non Current Assets Annual Cr 568431
    Total Current Assets Annual Cr 948914
    Total Assets Annual Cr 1,5161,345
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 2725
    ROE Annual % 119
    ROCE Annual % 1412
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2423
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 591560586531500486
    Operating Expenses Qtr Cr 462450453417398376
    Operating Profit Qtr Cr 128110133114102110
    Depreciation Qtr Cr 202122181414
    Interest Qtr Cr 353222
    Tax Qtr Cr 312330302621
    Net Profit Qtr Cr 897883846982
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 2,2281,911
    Operating Expenses Annual Cr 1,7191,513
    Operating Profit Annual in Cr 459339
    Depreciation Cr 7452
    Interest Annual Cr 119
    Tax Annual Cr 10972
    Net Profit Annual Cr 314266
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 230237
    Cash from Investing Activity Annual Cr -141-259
    Cash from Financing Annual Activity Cr -69198
    Net Cash Flow Annual Cr 21176
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 2,0651,745
    Fixed Assets Annual Cr 746458
    Total Non Current Assets Annual Cr 818515
    Total Current Assets Annual Cr 1,8621,675
    Total Assets Annual Cr 2,6812,190
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 4639
    ROE Annual % 1515
    ROCE Annual % 1919
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2322
    Invest in Marksans Pharma

    Marksans Pharma Technicals

    EMA & SMA

    Current Price
    ₹296.39
    + 2.68 (0.91%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹255.88
    • 50 Day
    • ₹226.48
    • 100 Day
    • ₹202.29
    • 200 Day
    • ₹176.51
    • 20 Day
    • ₹252.85
    • 50 Day
    • ₹219.68
    • 100 Day
    • ₹190.67
    • 200 Day
    • ₹174.11

    Marksans Pharma Resistance and Support

    PIVOT
    ₹293.14
    Resistance
    First Resistance 301.26
    Second Resistance 306.12
    Third Resistance 314.25
    RSI 79.72
    MFI 87.29
    MACD Single Line 17.20
    MACD 20.36
    Support
    First Support 288.27
    Second Support 280.14
    Third Supoort 275.28

    Marksans Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 3,773,309 140,404,828 37.21
    Week 4,123,669 137,565,611 33.36
    1 Month 4,562,131 140,604,873 30.82
    6 Month 3,007,878 112,073,548 37.26

    Marksans Pharma Result Highlights

    Marksans Pharma Synopsis

    NSE-Medical-Diversified

    Marksans Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.27 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2024. Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364.
    Market Cap 13,310
    Sales 926
    Shares in Float 25.38
    No of funds 108
    Yield 0.2
    Book Value 10.89
    U/D Vol ratio 2.9
    LTDebt / Equity
    Alpha 0.34
    Beta 1.12

    Marksans Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 43.87%43.85%43.85%43.85%
    Mutual Funds 2.82%4.23%3.82%3.15%
    Foreign Portfolio Investors 7.71%4.69%4.67%4.19%
    Financial Institutions/ Banks
    Individual Investors 29.47%30.91%30.8%32.12%
    Others 16.13%16.32%16.86%16.69%

    Marksans Pharma Management

    Name Designation
    Mr. Mark Saldanha Chairman & Managing Director
    Mrs. Sandra Saldanha Whole Time Director
    Mr. Varddhman V Jain Whole Time Director
    Dr. Sunny Sharma Non Executive Director
    Mr. Seetharama R Buddharaju Independent Director
    Mr. Digant Mahesh Parikh Independent Director
    Mr. Abhinna Sundar Mohanty Independent Director
    Mrs. Shailaja Vardhan Independent Director

    Marksans Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Marksans Pharma Corporate Action

    Date Purpose Remarks
    2024-08-13 Quarterly Results
    2024-05-30 Audited Results & Final Dividend
    2024-02-13 Quarterly Results
    2023-11-09 Quarterly Results
    2023-08-11 Quarterly Results
    Date Purpose Remarks
    2024-09-17 FINAL Rs.0.60 per share(60%)Final Dividend
    2023-06-07 FINAL Rs.0.50 per share(50%)Final Dividend

    Marksans Pharma MF Shareholding

    Name Amount(cr)
    Bandhan Small Cap Fund Regular Growth 7,534
    UTI Aggressive Hybrid Fund Regular Plan Growth 6,189
    UTI Retirement Fund - Regular Plan 4,705
    UTI Small Cap Fund Regular Growth 4,573
    UTI Large & Mid Cap Fund Regular Plan Growth 3,931

    Marksans Pharma FAQs

    What is Share Price of Marksans Pharma ?

    Marksans Pharma share price is ₹296 As on 18 September, 2024 | 02:24

    What is the Market Cap of Marksans Pharma ?

    The Market Cap of Marksans Pharma is ₹13431.3 Cr As on 18 September, 2024 | 02:24

    What is the P/E ratio of Marksans Pharma ?

    The P/E ratio of Marksans Pharma is 40.2 As on 18 September, 2024 | 02:24

    What is the PB ratio of Marksans Pharma ?

    The PB ratio of Marksans Pharma is 6.4 As on 18 September, 2024 | 02:24

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.